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Background: Many patients with severe aortic stenosis (AS) and coexisting conditions are not candidates for surgical aortic valve replacement 
(SAVR). For these patients, transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option. We sought to discover whether 
TAVI really can overcome the limitation of patient selection for SAVR in severe symptomatic AS patients.
methods: We divided 126 consecutive patients with symptomatic high-grade AS that underwent TAVI with the Edward SAPIEN prosthesis into two 
groups based on operability.
results: The overall patient population was old (84.8±8.0 years), with a high prevalence of percutaneous coronary intervention and/or coronary 
artery bypass graft history (62.7%). They were at high surgical risk (STS score, 11.4±3.5%, logistic EuroSCORE (LES), 28.4±17.0%). There were 20 
(15.9%) inoperable patients among total 126 patients. They were younger (78.9±12.8 vs. 85.9±6.2, p=.033) and had higher pulmonary arterial 
pressure (52.0±14.0 vs. 44.0±16.3 mmHg, p=.032) than operable patients. There were no difference of surgical risks (STS score, 11.3±6.7 vs. 
11.4±2.6, p=.413; LES, 28.9±16.6 vs. 28.3±17.1, p=.706) between the two groups. The follow-up duration was 11 months (IQR 6 to 12). In the 
first 30 days after the procedure, 8/126 (6.4%) patients died. The all-cause death rates were 19.8% and 23.8% at 6 and 12-month respectively. 
There were no statistical difference of all-cause death rates between inoperable and operable group at 6 (35.0% vs. 17.0%, p=.074) and 12 month 
(35.0% vs. 21.7%, p=.252) follow-up. The rates of rehospitalization from any cause (55.0% vs. 40.4%, p=.229) were also not significantly different 
between the two groups. High surgical risk was the independent predictor of mortality after procedure in the multivariate analysis.
conclusions: We have shown that in patients with severe symptomatic AS who were at high surgical risk, the difference in mortality or morbidity 
after TAVI at 6 and 12 month was insignificant between two groups. Our findings indicate that for selecting patients, the inoperable condition may 
not be a limitation for TAVI. And high surgical risk itself was helpful for predicting mortality after TAVI.
